Company Profile

SHINE Medical Technologies Inc (AKA: Shine Medical Technologies LLC)
Profile last edited on: 9/27/21      CAGE: 69GY5      UEI: ULJNHSVK5AP8

Business Identifier: Medical tracers and cancer treatment elements: radioisotopes for nuclear medicine
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

101 East Milwaukee Street Suite 600
Janesville, WI 53713
   (608) 210-1061
Location: Single
Congr. District: 02
County: Dane

Public Profile

Spun out of research conducted at the University of Wisconsin Madison, SHINE Medical Technologies Inc manufactures and supplies medical tracers and cancer treatment elements and is working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented proprietary manufacturing process offering major advantages over existing and proposed production technologies: does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for moly-99. The company offers Molybdenum-99, a light-emitting element that is administered to patients for the purpose of diagnosing and staging cancer and heart diseases. To an extent, the firm is focused on developent of cost-effective and greener production methods to address US shortage of molybdenum-99 medical isotope. SHINE Medical also provides Iodine-131 that is used to treat thyroid cancer and various abnormal thyroid conditions, including hyper-thyroidism, as well as to diagnose liver function, renal blood flow, and urinary tract obstruction; and Iodine-125 that is used in the treatment of prostate cancer and brain tumors, as well as to evaluate kidney function and diagnose deep vein thrombosis in the leg; and Xenon-133 that is inhaled as a gas to evaluate regional function in emphysema and various forms of chronic and obstructive lung diseases

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 1 NSF $149,743
Project Title: Development of a Novel Process for the Manufacture of Iodine-131 for Medical Use

Key People / Management

  Todd Asmuth -- President

  Gregory R Piefer -- Founder and CEO

  Jim Costedio -- Vice President Regulatory Affairs & Quality

  Jeff Driscoll

  George Hansrote -- VP Project Delivery

  Stephen C Hathaway -- CFO

  Darin Janecek -- Chief Financial Officer

  Chris Lee -- Chief Financial Officer VP

  Katrina Pitas -- Vice President, Business Development

  Ross Radel -- Chief Technology Officer

  Tracy Radel -- Vice President of Engineering

  Eric Schutt -- Chief of Staff & Vice President Government Affairs

  Richard Vann Bynum -- Chief Operations Officer